Investigational Drug Details
| Drug ID: | D015 |
| Drug Name: | Serine |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB00133 |
| DrugBank Description: | A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from glycine or threonine. It is involved in the biosynthesis of purines; pyrimidines; and other amino acids. |
| PubChem ID: | 5951 |
| CasNo: | 56-45-1 |
| Repositioning for NAFLD: | Yes |
| SMILES: | N[C@@H](CO)C(O)=O |
| Structure: |
|
| InChiKey: | MTCFGRXMJLQNBG-REOHCLBHSA-N |
| Molecular Weight: | 105.0926 |
| DrugBank Targets: | Cystathionine beta-synthase; L-serine dehydratase/L-threonine deaminase; Serine racemase; Serine palmitoyltransferase 2; Serine palmitoyltransferase 1; Serine--tRNA ligase, cytoplasmic; Serine--pyruvate aminotransferase |
| DrugBank MoA: | L-Serine plays a role in cell growth and development (cellular proliferation). The conversion of L-serine to glycine by serine hydroxymethyltransferase results in the formation of the one-carbon units necessary for the synthesis of the purine bases, adenine and guanine. These bases when linked to the phosphate ester of pentose sugars are essential components of DNA and RNA and the end products of energy producing metabolic pathways, ATP and GTP. In addition, L-serine conversion to glycine via this same enzyme provides the one-carbon units necessary for production of the pyrimidine nucleotide, deoxythymidine monophosphate, also an essential component of DNA. |
| DrugBank Pharmacology: | Serine is classified as a nutritionally non-essential amino acid. Serine is critical for the production of the body's proteins, enzymes and muscle tissue. Serine is needed for the proper metabolism of fats and fatty acids. It also helps in the production of antibodies. Serine is used as a natural moisturizing agent in some cosmetics and skin care products. The main source of essential amino acids is from the diet, non-essential amino acids are normally synthesize by humans and other mammals from common intermediates. |
| DrugBank Indication: | Used as a natural moisturizing agent in some cosmetics and skin care products. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L4429 | NCT01495013 | PHASE3 | COMPLETED | NO | 2011-12 | 2016-11-21 | Details |
| L5066 | NCT00321321 | PHASE2 | COMPLETED | YES | 2006-05 | 2015-07-16 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00027 | 11533494 | Science | Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. | Details |
| A00065 | 15166380 | Science | A family with severe insulin resistance and diabetes due to a mutation in AKT2. | Details |
| A00123 | 1963473 | Mol Endocrinol | Functional properties of a naturally occurring Trp1200----Ser1200 mutation of the insulin receptor. | Details |
| A00134 | 20574426 | J Hum Genet | The GCKR rs780094 polymorphism is associated with susceptibility of type 2 diabetes, reduced fasting plasma glucose levels, increased triglycerides levels and lower HOMA-IR in Japanese population. | Details |
| A00136 | 21118154 | Biochem J | LKB1 is required for hepatic bile acid transport and canalicular membrane integrity in mice. | Details |
| A00137 | 21186350 | Nat Genet | Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. | Details |
| A00143 | 23275527 | J Clin Endocrinol Metab | Genotype and phenotype correlations in 417 children with congenital hyperinsulinism. | Details |
| A00155 | 25741167 | World J Gastroenterol | Hepatic phenotypes of HNF1B gene mutations: a case of neonatal cholestasis requiring portoenterostomy and literature review. | Details |